Mary Nesline
- Oncology top 5%
- Molecular Biology
- Immunology top 10%
- Cancer Research top 10%
- Pulmonary and Respiratory Medicine
- Co-authors
- Sarabjot PablaWarren DavisJeffrey M. ConroyChristine B. AmbrosonePaul DePietroRazelle KurzrockShumei KatoSusan E. McCann
- Topics
- Cancer Immunotherapy and Biomarkers (43 papers)Cancer Genomics and Diagnostics (19 papers)Immunotherapy and Immune Responses (15 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaThe Journal of Immunology
- Partner nations
- United StatesFranceNetherlands
In The Last Decade
Mary Nesline
62 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Oncology 503
- Molecular Biology 414
- Immunology 261
- Cancer Research 261
- Pulmonary and Respiratory Medicine 193
Countries citing papers authored by Mary Nesline
This map shows the geographic impact of Mary Nesline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Nesline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Nesline more than expected).
Fields of papers citing papers by Mary Nesline
This network shows the impact of papers produced by Mary Nesline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Nesline. The network helps show where Mary Nesline may publish in the future.
Co-authorship network of co-authors of Mary Nesline
This figure shows the co-authorship network connecting the top 25 collaborators of Mary Nesline. A scholar is included among the top collaborators of Mary Nesline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Nesline. Mary Nesline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 18 | |
| 2 | 3 | |
| 3 | 3 | |
| 4 | 28 | |
| 5 | 0 | |
| 6 | 6 | |
| 7 | 1 | |
| 8 | 4 | |
| 9 | 0 | |
| 10 | 9 | |
| 11 | 24 | |
| 12 | 15 | |
| 13 | 0 | |
| 14 | 1 | |
| 15 | 24 | |
| 16 | 0 | |
| 17 | 56 | |
| 18 | 25 | |
| 19 | 88 | |
| 20 | The presence of the FRA12E/SMRT fragile site in the genome of prostate cancer patients is a predictor of metastatic development | 1 |
About Mary Nesline
Mary Nesline is a scholar working on Oncology, Cancer Research and Immunology, having authored 73 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (43 papers), Cancer Genomics and Diagnostics (19 papers) and Immunotherapy and Immune Responses (15 papers). The work is most often cited by research in Biological Psychiatry (51 citations), Oncology (503 citations) and Cancer Research (261 citations). Mary Nesline has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Sarabjot Pabla, Warren Davis, Jeffrey M. Conroy, Christine B. Ambrosone, Paul DePietro, Razelle Kurzrock, Shumei Kato, Susan E. McCann, Yu Fujiwara and Chi-Chen Hong. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.